default author photo

Johan Bodegård

AstraZeneca Pharmaceuticals - Cardiovascular, Renal and Metabolism

Oslo

Norway

SCHOLARLY PAPERS

2

DOWNLOADS

250

TOTAL CITATIONS

3

Scholarly Papers (2)

1.

Prevalence, Outcomes, and Cost of CKD in a Contemporary Population of 2·4 Million Patients from 11 Countries: The CaReMe CKD Study

Number of pages: 34 Posted: 04 Jan 2022
Uppsala University - Clinical Epidemiology Unit, AstraZeneca Pharmaceuticals - Cardiovascular, Renal and Metabolism, University of Leipzig - Heart Center, University of Amsterdam - Department of Nephrology, Government of the United Kingdom - Queen Elizabeth University Hospital, Maccabi HealthCare Services - Kahn Sagol Maccabi (KSM) Research & Innovation Center, Universidade do Porto - Department of Community Medicine, Information and Health Decision Sciences, Hospital Universitario Lucus Augusti (HULA), University of Oslo - Institute of Clinical Medicine, Statisticon AB, University of Zurich - Institute of Primary Care, University of Ottawa - Ottawa Hospital Research Institute, KU Leuven - Department of Public Health and Primary Care, University of Manitoba - Department of Internal Medicine and Independent
Downloads 158 (472,207)
Citation 3

Abstract:

Loading...

Chronic kidney disease, renal impairment, prevalence, epidemiology, outcomes, costs, primary care, public health, global health

2.

History of Heart Failure and Chronic Kidney Disease and the Risk for Allcause Death after COVID-19 During the Three First Waves in Comparison to Influenza Outbreaks in Sweden

Number of pages: 33 Posted: 05 Apr 2022
Karolinska Institutet - Division of Cardiology, AstraZeneca Pharmaceuticals - Cardiovascular, Renal and Metabolism, Uppsala University, Statisticon AB, Karolinska Institutet, Karolinska Institutet, Uppsala University - Department of Medical Sciences, Clinical Diabetes and Metabolism and Karolinska Institutet
Downloads 92 (730,864)

Abstract:

Loading...

Heart failure, Renal failure, COVID-19, Influenza, Prognosis